Skip to main content
Funded Studies

William Dvořák Shrader, PhD

Chief Scientific Officer at CuraX Therapeutics Corporation

Location: Palo Alto, CA United States

William Shrader, PhD, has 26 years of experience in the pharmaceutical industry. During the last 14 years, he has led teams that have advanced 3 drugs into the clinic for neurodegenerative diseases. These drugs have completed phase 2 clinical trials in Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Friedriech’s ataxia, Rett Syndrome, and Leigh syndrome. Dr. Shrader has also successfully led a team for the development of clinical biomarkers for a Phase 2 ALS trial, demonstrating target engagement.

Dr. Shrader earned his doctorate in organic chemistry at the University of California, Berkeley and completed a post-doctoral fellowship at Caltech.

Associated Grants

  • Pre-clinical Development of Compounds that Modulate Mitophagy through Regulation of the Mitochondrial GTPase Miro1


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.